Therapeutic anti-cancer targets upstream of the proteasome

Grzegorz Nalepa, J. Wade Harper

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Polyubiquitination of a protein is generally the first step in its degradation. This article discusses how altered protein destruction pathways impact the cell cycle and allow for abnormal cell proliferation, and explores how this process can be utilized in anticancer therapy. There are several levels of possible therapeutic intervention in ubiquitin-dependent proteolysis pathways upstream of the proteasome. In principle, targeting specific components of the ubiquitin system may offer an opportunity to develop selective drugs. However, the fact that general proteasome inhibitors have been demonstrated to be effective in cancer therapy suggests that other ubiquitin components that are common to many destruction pathways may also be clinically useful. We will, therefore, evaluate both the specific, rate-limiting enzymes and a number of general, nonselective enzymes as targets for anticancer therapy. Potential nonselective therapeutic strategies that are under investigation in a variety of human cancers include the identification and inhibition of individual F-box proteins, such as Skp2, and the inhibition of the ubiquitin ligases such as the SCF family, Mdm2, and Efp. A general pathway under investigation is the cullin neddylation and deneddylation system, with promising enzymatic targets such as csn5 and Rpn11.

Original languageEnglish (US)
Pages (from-to)49-57
Number of pages9
JournalCancer Treatment Reviews
Volume29
Issue numberSUPPL. 1
DOIs
StatePublished - May 2003
Externally publishedYes

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Neoplasms
Cullin Proteins
F-Box Proteins
Therapeutics
Proteasome Inhibitors
Enzymes
Ligases
Proteolysis
Cell Cycle
Proteins
Cell Proliferation
Pharmaceutical Preparations

Keywords

  • Cullin
  • F-box protein
  • Nedd8
  • Oncogene
  • Proteasome
  • Proteolysis
  • Therapeutic
  • Ubiquitin ligase

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Therapeutic anti-cancer targets upstream of the proteasome. / Nalepa, Grzegorz; Harper, J. Wade.

In: Cancer Treatment Reviews, Vol. 29, No. SUPPL. 1, 05.2003, p. 49-57.

Research output: Contribution to journalReview article

Nalepa, Grzegorz ; Harper, J. Wade. / Therapeutic anti-cancer targets upstream of the proteasome. In: Cancer Treatment Reviews. 2003 ; Vol. 29, No. SUPPL. 1. pp. 49-57.
@article{04a0d207eb994ed6810fded37d6760e4,
title = "Therapeutic anti-cancer targets upstream of the proteasome",
abstract = "Polyubiquitination of a protein is generally the first step in its degradation. This article discusses how altered protein destruction pathways impact the cell cycle and allow for abnormal cell proliferation, and explores how this process can be utilized in anticancer therapy. There are several levels of possible therapeutic intervention in ubiquitin-dependent proteolysis pathways upstream of the proteasome. In principle, targeting specific components of the ubiquitin system may offer an opportunity to develop selective drugs. However, the fact that general proteasome inhibitors have been demonstrated to be effective in cancer therapy suggests that other ubiquitin components that are common to many destruction pathways may also be clinically useful. We will, therefore, evaluate both the specific, rate-limiting enzymes and a number of general, nonselective enzymes as targets for anticancer therapy. Potential nonselective therapeutic strategies that are under investigation in a variety of human cancers include the identification and inhibition of individual F-box proteins, such as Skp2, and the inhibition of the ubiquitin ligases such as the SCF family, Mdm2, and Efp. A general pathway under investigation is the cullin neddylation and deneddylation system, with promising enzymatic targets such as csn5 and Rpn11.",
keywords = "Cullin, F-box protein, Nedd8, Oncogene, Proteasome, Proteolysis, Therapeutic, Ubiquitin ligase",
author = "Grzegorz Nalepa and Harper, {J. Wade}",
year = "2003",
month = "5",
doi = "10.1016/S0305-7372(03)00083-5",
language = "English (US)",
volume = "29",
pages = "49--57",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Therapeutic anti-cancer targets upstream of the proteasome

AU - Nalepa, Grzegorz

AU - Harper, J. Wade

PY - 2003/5

Y1 - 2003/5

N2 - Polyubiquitination of a protein is generally the first step in its degradation. This article discusses how altered protein destruction pathways impact the cell cycle and allow for abnormal cell proliferation, and explores how this process can be utilized in anticancer therapy. There are several levels of possible therapeutic intervention in ubiquitin-dependent proteolysis pathways upstream of the proteasome. In principle, targeting specific components of the ubiquitin system may offer an opportunity to develop selective drugs. However, the fact that general proteasome inhibitors have been demonstrated to be effective in cancer therapy suggests that other ubiquitin components that are common to many destruction pathways may also be clinically useful. We will, therefore, evaluate both the specific, rate-limiting enzymes and a number of general, nonselective enzymes as targets for anticancer therapy. Potential nonselective therapeutic strategies that are under investigation in a variety of human cancers include the identification and inhibition of individual F-box proteins, such as Skp2, and the inhibition of the ubiquitin ligases such as the SCF family, Mdm2, and Efp. A general pathway under investigation is the cullin neddylation and deneddylation system, with promising enzymatic targets such as csn5 and Rpn11.

AB - Polyubiquitination of a protein is generally the first step in its degradation. This article discusses how altered protein destruction pathways impact the cell cycle and allow for abnormal cell proliferation, and explores how this process can be utilized in anticancer therapy. There are several levels of possible therapeutic intervention in ubiquitin-dependent proteolysis pathways upstream of the proteasome. In principle, targeting specific components of the ubiquitin system may offer an opportunity to develop selective drugs. However, the fact that general proteasome inhibitors have been demonstrated to be effective in cancer therapy suggests that other ubiquitin components that are common to many destruction pathways may also be clinically useful. We will, therefore, evaluate both the specific, rate-limiting enzymes and a number of general, nonselective enzymes as targets for anticancer therapy. Potential nonselective therapeutic strategies that are under investigation in a variety of human cancers include the identification and inhibition of individual F-box proteins, such as Skp2, and the inhibition of the ubiquitin ligases such as the SCF family, Mdm2, and Efp. A general pathway under investigation is the cullin neddylation and deneddylation system, with promising enzymatic targets such as csn5 and Rpn11.

KW - Cullin

KW - F-box protein

KW - Nedd8

KW - Oncogene

KW - Proteasome

KW - Proteolysis

KW - Therapeutic

KW - Ubiquitin ligase

UR - http://www.scopus.com/inward/record.url?scp=0038189900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038189900&partnerID=8YFLogxK

U2 - 10.1016/S0305-7372(03)00083-5

DO - 10.1016/S0305-7372(03)00083-5

M3 - Review article

C2 - 12738243

AN - SCOPUS:0038189900

VL - 29

SP - 49

EP - 57

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - SUPPL. 1

ER -